Clinically, most evidences have showed that HCP5 overexpression is associated with the clinicopathological characteristics and prognosis of various cancers, including gastric cancer [16, 17], non-small cell lung cancer [18], renal cell carcinoma [19] and osteosarcoma [20]. Here, HCP5 is linked to non-small cell lung carcinoma.